Navigation Links
XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter
Date:2/5/2009

VALLEY COTTAGE, N.Y., Feb. 5 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today provided notification that on February 3, 2009 the Company received a letter from a shareholder who owns more than 5% of the Company's outstanding ordinary shares requesting the convening of an extraordinary shareholders' meeting (EGM) of the Company as soon as possible to address and approve the following matters:

1. that Boaz Shweiger be and is hereby appointed as a Director of the Company until the next annual general meeting of the Company;

2. that Mark Allouche be and is hereby appointed as a Director of the Company until the next annual general meeting of the Company;

3. that Amit Yonay be and is hereby appointed as a Director of the Company until the next annual general meeting of the Company;

4. that David Grossman be and is hereby appointed as a Director of the Company until the next annual general meeting of the Company;

5. that Michael Weiss, Samuel Rudman and William Kennedy be removed from their role as Directors of the Company;

6. that Yaron Diament be and is hereby appointed as an External Director of the Company until March 11, 2012;

7. that Dafna Cohen be and is hereby appointed as an External Director of the Company until March 11, 2012;

8. that the share capital of the Company be consolidated and re-divided so that each five (5) shares of NIS 0.02 nominal value shall be consolidated into one (1) share of NIS 0.1 nominal value;

9. that the registered share capital of the Company be increased from NIS 10,000,000 divided into 100,000,000 ordinary shares, NIS 0.1 nominal value, to NIS 70,000,000 divided into 700,000,000 ordinary shares, NIS 0.1 nominal value;

10. that the ADR ratio be amended from one (1) ADR representing two (2) ordinary shares, NIS 0.1 nominal value, to one (1) ADR representing twenty (20) ordinary shares, NIS 0.1 nominal value;

11. and that the remuneration terms for Boaz Shweiger, Mark Allouche, Amit Yonay, David Grossman, Yaron Diament and Dafna Cohen, as set forth in the Notice is hereby approved.

The EGMs will take place at the Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 3:00 p.m. and 5:30 p.m. Israel time on March 11, 2009.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
2. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
5. XTL Biopharmaceuticals Implements Restructuring Plan
6. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
7. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
8. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
9. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
10. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
11. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... 12, 2017 , ... Huffman Engineering, Inc. , a leader in control ... the company’s Lincoln office as a chemical engineer. In his new role, Beck ... in the life science manufacturing and water/wastewater industries. , Prior to joining Huffman Engineering, ...
(Date:1/12/2017)... India , January 12, 2017 A new report published ... End Users - Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the global ... in 2015, growing at a CAGR of 15.07% during the forecast period. ... ... Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... specialists with accurate and reliable preimplantation genetic screening (PGS). , “Our genetics and ... results,” says Ovation Fertility Genetics Scientific Director Amy Jones, M.S., ELD (ABB) ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... and costing healthcare systems more than $23.7 billion, healthcare systems are looking ... , Among the most common sepsis-causing pathogens are bacteria and the yeast pathogen ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
(Date:12/15/2016)... 15, 2016  There is much more to innovative ... the engine. Continental will demonstrate the intelligence of today,s ... . Through the combination of the keyless entry ... biometric elements, the international technology company is opening up ... authentication. "The integration of biometric elements brings ...
Breaking Biology News(10 mins):